reference/21112626

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21112626

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	7
issn	0361-5960
issueIdentifier	6
pageRange	731-7
publicationName	Cancer treatment reports
startingPage	731
bibliographicCitation	Hurteloup P, Armand JP, Cappelaere P, Metz R, Kerbrat P, Keiling R, Fumoleau P, Fargeot P, Schraub S, Bastit P. Phase II clinical evaluation of doxifluridine. Cancer Treat Rep. 1986 Jun;70(6):731–7. PMID: 2942245.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e0d64e2965c22ff853b1a05e64c17e5c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9a6c7bc089d0cfe34e0272693d8a1ee2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_42a1bc20584ef41319705d883db89629 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3ee3e3e64872b1b1c2f11436dc87dd6d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_26dfb2a133085332a382fa80d684c124 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0bc1647d677fe8717684827969acb02f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_233bd0722b6712e22246f9e99ebacaf1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2724a1c1fbee27632de202da641ac378 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8f23d2eceb3fd455a7a8335ade2e5fcb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_301ea5c49addcc4e6a2e9cf2e9838a40
date	198606
identifier	https://pubmed.ncbi.nlm.nih.gov/2942245
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2790 https://portal.issn.org/resource/ISSN/0361-5960
language	English
source	https://pubmed.ncbi.nlm.nih.gov/
title	Phase II clinical evaluation of doxifluridine
discusses	http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0083927 http://id.nlm.nih.gov/mesh/M0008626
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D005467Q000627 http://id.nlm.nih.gov/mesh/D009369Q000188 http://id.nlm.nih.gov/mesh/D000970Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D002493Q000139 http://id.nlm.nih.gov/mesh/D003110Q000188 http://id.nlm.nih.gov/mesh/D006331Q000139 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D009369Q000473 http://id.nlm.nih.gov/mesh/D004341 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000505Q000139 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D001943Q000188 http://id.nlm.nih.gov/mesh/D008207 http://id.nlm.nih.gov/mesh/D007263 http://id.nlm.nih.gov/mesh/D007680Q000188 http://id.nlm.nih.gov/mesh/D005467Q000009 http://id.nlm.nih.gov/mesh/D012004Q000188 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D006402Q000139 http://id.nlm.nih.gov/mesh/D009325Q000139 http://id.nlm.nih.gov/mesh/D000368
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9672 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8752 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9950 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9060 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10523 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280352 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7170 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18343 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7078 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8652 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8237 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7306 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9305 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8096

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID76715693

Total number of triples: 73.